Natera, Inc. (NASDAQ:NTRA – Get Rating) has been given a consensus recommendation of “Buy” by the thirteen research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 1 year price objective […]
Natera (NASDAQ:NTRA – Get Rating) had its price target reduced by equities research analysts at Piper Sandler from $75.00 to $60.00 in a research note issued to investors on Sunday, The Fly reports. Piper Sandler’s target price would suggest a potential upside of 75.44% from the stock’s previous close. A number of other research analysts […]
Natera, Inc. (NASDAQ:NTRA – Get Rating) CEO Steven Leonard Chapman sold 894 shares of the business’s stock in a transaction dated Friday, April 22nd. The shares were sold at an average price of $36.14, for a total transaction of $32,309.16. Following the completion of the sale, the chief executive officer now directly owns 63,122 shares […]
Natera (NASDAQ:NTRA – Get Rating) had its price target increased by equities research analysts at Piper Sandler from $70.00 to $75.00 in a report issued on Wednesday, The Fly reports. The brokerage currently has an “overweight” rating on the medical research company’s stock. Piper Sandler’s target price would suggest a potential upside of 83.60% from […]
Natera, Inc. (NASDAQ:NTRA – Get Rating) has earned an average rating of “Buy” from the fourteen research firms that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. The […]